ArticleFrontiers in psychiatry2025
Case report: Recurrent catatonia in a patient with 17p13.3 microduplication syndrome.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catatonia is a clinically significant syndrome with various etiologies, including genetic factors, that are increasingly recognized. We present a case of recurrent catatonia associated with 17p13.3 microduplication syndrome in a 47-year-old woman with a long-standing history of recurrent depressive episodes. At age 44, she experienced her first episode with psychotic and catatonic features, which required hospitalization. Over the next three years, she had four additional catatonic episodes. Four years after her initial presentation, she was diagnosed with 17p13.3 microduplication syndrome. This case emphasizes the importance of considering genetic testing for patients with recurrent catatonia, particularly those with a comorbid developmental disorder. Given the limited number of cases of 17p13.3 microduplication syndrome reported in the literature, we share these findings to encourage prompt genetic assessment in similar presentations. Clinicians treating patients with catatonia should recognize the prevalence of medical, and particularly genetic, disorders that increase susceptibility to catatonia. Conversely, clinicians working with patients who have genetically based neurodevelopmental syndromes should be aware of the challenges in diagnosing and treating catatonia. By identifying catatonia in this patient population, prompt and targeted interventions that may significantly reduce the disabling effects of catatonia can be initiated. This case also expands the known phenotypic spectrum of 17p13.3 microduplication syndrome and contributes to understanding the genetic factors involved in catatonia, though further research is needed to clarify this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.